Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023

Business by 2FIRSTS.ai
Feb.02.2024
Altria Releases Financial Report for Q4 2023 and Full Year, Net Revenue Reaching $24.48 Billion for 2023
Tobacco company Altschuyler reported a 2.2% decrease in Q4 and 2.4% decrease in full-year net revenues for 2023.

Altria Corporation, the official website, recently released its financial report for the fourth quarter and full year of 2023.

 

Altriai's net revenue in the fourth quarter of 2023 amounted to $5.98 billion, with a total net revenue of $24.48 billion for the entire fiscal year. This represents a decrease of 2.2% and 2.4% compared to the same period in 2022, respectively. The adjusted earnings per share for the fourth quarter remained unchanged at $1.18, as compared to the previous year.

 

According to a report released by ABC Company, the overall decline in net income was primarily attributed to a decrease in the revenue of the combustible tobacco products division. This decrease partially offset the increase in net income observed in the oral tobacco products division.

 

Ocheria expects its adjusted earnings per share for the full year of 2024 to be within the range of $5.00 to $5.15. This represents a growth rate of 1% to 4% compared to the baseline of $4.95 in 2023.

 

Billy Gifford, Chief Executive Officer of Orchia, has stated that electronic vaping products continue to be the most popular smoke-free products, with a growth of approximately 35% last year. However, a significant portion of this growth comes from illegally flavored disposable products, which account for half of the market share. Gifford stated, "The current state of the market is unacceptable for both legitimate manufacturers and consumers. These products are distributed by companies that have violated almost all regulations and guidelines issued by the US Food and Drug Administration since 2016.

 

Investors should take note that Altriai has enhanced shareholder returns through share buybacks and dividend payments.

 

In 2023, Ochiya repurchased 22.7 million shares at an average price of $43.96, returning $1 billion in cash to shareholders. The company's board of directors has now authorized a new $1 billion stock repurchase plan, expected to be completed by the end of 2024.

 

In August of last year, AAltria increased its dividend by 4.3%, marking the 58th dividend growth in the past 54 years. According to the financial report, dividends paid in the fourth quarter amounted to $1.7 billion, while dividends projected for 2023 are estimated at $6.8 billion.

 

In 2018, Altria acquired a 35% stake in e-cigarette company JUUL Labs for a total investment of $12.8 billion. However, the company faced legal challenges related to youth smoking as JUUL was accused of aggressively targeting the teenage market.

 

As of the end of 2022, Altria's valuation of JUUL has plummeted to only $250 million.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

State Registries Are Reshaping U.S. Vape Market Access 2Firsts Interview with U.S. Vapor Manufacturers Association President Allison Boughner
State Registries Are Reshaping U.S. Vape Market Access 2Firsts Interview with U.S. Vapor Manufacturers Association President Allison Boughner
As the U.S. vapor market faces FDA authorizations, import seizures and growing state-level restrictions, AVM President Allison Boughner told 2Firsts that state product registries and white-list systems are having the most immediate impact. She said distributors are placing greater weight on documentation, product origin and supply-chain transparency.
Special Report
May.26
New Movement Emerges on EU Tobacco Excise Directive as Cyprus Tables Compromise Draft
New Movement Emerges on EU Tobacco Excise Directive as Cyprus Tables Compromise Draft
The long-stalled debate over the European Union’s Tobacco Excise Directive may be moving forward, with Cyprus, as holder of the EU Council presidency, putting forward a compromise draft. The reported proposal includes lowering the minimum excise duty requirement and granting a transitional period, with the aim of reaching political agreement by June 2026. The revision also covers e-cigarettes, heated tobacco, nicotine pouches and stronger controls on raw tobacco.
Apr.21 by 2FIRSTS.ai
UK Bill Banning Tobacco Sales to People Born After 2008 Clears Parliament
UK Bill Banning Tobacco Sales to People Born After 2008 Clears Parliament
A UK bill banning the legal sale of tobacco to people born on or after January 1, 2009 has completed its passage through parliament. Under the bill, those born in that group will never be able to be legally sold tobacco anywhere in the UK. The legislation is expected to receive royal assent next week. It also gives ministers powers to strengthen public-place smoking restrictions and restricts branding, promotion and advertising of vape and nicotine products aimed at children.
Apr.22 by 2FIRSTS.ai
Serbian Parliament Passes Trade Laws Banning Sales of E-Cigarettes and Nicotine Products to Minors
Serbian Parliament Passes Trade Laws Banning Sales of E-Cigarettes and Nicotine Products to Minors
Serbia’s parliament has adopted a package of trade laws aimed at increasing consumer protection while introducing a range of changes for merchants and online platforms. One of the most important new measures is a ban on the sale of e-cigarettes and other nicotine products to minors, tightening youth protection rules.
Apr.24 by 2FIRSTS.ai
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
According to public records from China’s National Intellectual Property Administration, a patent application filed by China Tobacco Yunnan Industrial Co., Ltd. for “cigar flavor granules” was published on May 12, 2026. The filing proposes purifying an ethanol extract of cigar tobacco leaves using LX-8 macroporous resin, followed by encapsulation with maltodextrin and sucrose fatty acid ester to improve smoking comfort, reduce dryness and enhance aroma release stability in reconstituted tobacco.
Jun.10
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai